BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families

被引:68
作者
Antoniou, AC [1 ]
Durocher, F
Smith, P
Simard, J
Easton, DF
机构
[1] Univ Cambridge, Dept Publ Hlth & Primary Care, Strangeways Res Lab, Canc Res UK Genet Epidemiol Unit, Cambridge, England
[2] Univ Quebec, Ctr Hosp, Oncol & Mol Endocrinol Res Ctr, Canc Genom Lab, Quebec City, PQ, Canada
[3] Univ Laval, Quebec City, PQ, Canada
关键词
D O I
10.1186/bcr1365
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Introduction Several genetic risk models for breast and ovarian cancer have been developed, but their applicability to specific populations has not been evaluated. We used data from French-Canadian families to evaluate the mutation predictions given by the BRCAPRO and BOADICEA models. We also used this data set to estimate the age-specific risks for breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Methods A total of 195 families with multiple affected individuals with breast or ovarian cancer were recruited through the INHERIT (INterdisciplinary HEalth Research International Team on BReast CAncer susceptibility) BRCAs research program. Observed BRCA1 and BRCA2 mutation status was compared with predicted carrier probabilities under the BOADICEA and BRCAPRO models. The models were assessed using Brier scores, attributes diagrams and receiver operating characteristic curves. Log relative risks for breast and ovarian cancer in mutation carriers versus population risks were estimated by maximum likelihood, using a modified segregation analysis implemented in the computer program MENDEL. Twenty-five families were eligible for inclusion in the BRCA1 penetrance analysis and 27 families were eligible for the BRCA2 penetrance analysis. Results The BOADICEA model predicted accurately the number of BRCA1 and BRCA2 mutations for the various groups of families, and was found to discriminate well at the individual level between carriers and noncarriers. BRCAPRO over-predicted the number of mutations in almost all groups of families, in particular the number of BRCA1 mutations. It significantly overestimated the carrier frequency for high predicted probabilities. However, it discriminated well between carriers and noncarriers. Receiver operating characteristic (ROC) curves indicate similar sensitivity and specificity for BRCAPRO and BOADICEA. The estimated risks for breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers were consistent with previously published estimates. Conclusion The BOADICEA model predicts accurately the carrier probabilities in French-Canadian families and may be used for counselling in this population. None of the penetrance estimates was significantly different from previous estimates, suggesting that previous estimates may be appropriate for counselling in this population.
引用
收藏
页数:12
相关论文
共 52 条
[1]
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].
Antoniou, A ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Loman, N ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130
[2]
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations:: a combined analysis of 22 population based studies [J].
Antoniou, AC ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
JOURNAL OF MEDICAL GENETICS, 2005, 42 (07) :602-603
[3]
The BOADICEA model of genetic susceptibility to breast and ovarian cancer [J].
Antoniou, AC ;
Pharoah, PPD ;
Smith, P ;
Easton, DF .
BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1580-1590
[4]
Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a defined personal and family history in an Ashkenazi Jewish woman (LAMBDA) [J].
Apicella, C ;
Andrews, L ;
Hodgson, SV ;
Fisher, SA ;
Lewis, CM ;
Solomon, E ;
Tucker, K ;
Friedlander, M ;
Bankier, A ;
Southey, MC ;
Venter, DJ ;
Hopper, JL .
BREAST CANCER RESEARCH, 2003, 5 (06) :R206-R216
[5]
AVARD D, 2005, IN PRESS FAM CANC
[6]
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes [J].
Berry, DA ;
Iversen, ES ;
Gudbjartsson, DF ;
Hiller, EH ;
Garber, JE ;
Peshkin, BN ;
Lerman, C ;
Watson, P ;
Lynch, HT ;
Hilsenbeck, SG ;
Rubinstein, WS ;
Hughes, KS ;
Parmigiani, G .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) :2701-2712
[7]
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history [J].
Berry, DA ;
Parmigiani, G ;
Sanchez, J ;
Schildkraut, J ;
Winer, E .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (03) :227-238
[8]
Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310
[9]
Brier G.W., 1950, Monthly Weather Review, V78, P1, DOI [10.1175/1520-0493(1950)078andlt
[10]
0001:VOFEITandgt